BACKGROUND: The diagnostic value of circulating mRNA for the early detection of primary and recurrent gastric cancer was evaluated. PATIENTS AND METHODS: Circulating hTERT and MUC1 mRNA were amplified in the plasma from 52 gastric cancer patients (40 preoperative and 12 postoperative patients) and 20 healthy controls. The results were compared with those of a circulating cancer cell assay and methylation-specific polymerase chain reaction assay. RESULTS: Cell-free mRNA of the analyzed genes was detected in 6 (15%) preoperative gastric cancer patients (hTERT: 3 and MUC1: 4 patients) and 2 follow-up patients. These mRNAs were not detected in the plasma from healthy volunteers. There was no correlation between the results of the cell-free mRNA and the other assays. CONCLUSION: Detection of circulating cell-free mRNA might serve as a new complementary tumor marker for gastric cancer.
BACKGROUND: The diagnostic value of circulating mRNA for the early detection of primary and recurrent gastric cancer was evaluated. PATIENTS AND METHODS: Circulating hTERT and MUC1 mRNA were amplified in the plasma from 52 gastric cancerpatients (40 preoperative and 12 postoperative patients) and 20 healthy controls. The results were compared with those of a circulating cancer cell assay and methylation-specific polymerase chain reaction assay. RESULTS: Cell-free mRNA of the analyzed genes was detected in 6 (15%) preoperative gastric cancerpatients (hTERT: 3 and MUC1: 4 patients) and 2 follow-up patients. These mRNAs were not detected in the plasma from healthy volunteers. There was no correlation between the results of the cell-free mRNA and the other assays. CONCLUSION: Detection of circulating cell-free mRNA might serve as a new complementary tumor marker for gastric cancer.
Authors: Ulrike Stein; Susen Burock; Pia Herrmann; Ina Wendler; Markus Niederstrasser; Klaus-Dieter Wernecke; Peter M Schlag Journal: J Mol Diagn Date: 2011-03 Impact factor: 5.568
Authors: H Takeshita; D Ichikawa; S Komatsu; M Tsujiura; T Kosuga; K Deguchi; H Konishi; R Morimura; A Shiozaki; H Fujiwara; K Okamoto; E Otsuji Journal: Br J Cancer Date: 2010-04-13 Impact factor: 7.640